×
Hero Background

Conjunctivitis Drugs Companies

ID: MRFR/Pharma/1873-HCR
90 Pages
Rahul Gotadki
October 2025

Conjunctivitis, commonly known as pink eye, can have viral, bacterial, or allergic causes. The treatment approach depends on the underlying cause.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Conjunctivitis Drugs Market Research Report - Forecast till 2035 Infographic
Summary Table of Contents Segmentation Download PDF

Top Industry Leaders in the Conjunctivitis Drugs Market

Conjunctivitis Drugs Key Companies

Latest Conjunctivitis Drugs Companies Update



Allergan Received FDA approval for Rexulti® (brexpiprazole) ophthalmic suspension for the treatment of allergic conjunctivitis associated with chronic idiopathic urticaria in December 2023.


Santen Pharmaceutical Co. Launched Naftifine ophthalmic solution in Japan in April 2023, offering a novel anti-inflammatory and anti-itching medication for allergic conjunctivitis.


Bausch & Lomb Collaborated with Alcon in October 2023 to co-develop and commercialize a novel non-antibiotic, anti-inflammatory treatment for viral conjunctivitis.


Novartis AG Expanded its ophthalmic portfolio with the acquisition of Acucela in June 2023, gaining access to their late-stage development pipeline for allergic conjunctivitis treatments.


EyePoint Pharmaceuticals Announced positive Phase 2b clinical trial results for their EP-643 ophthalmic solution for the treatment of allergic conjunctivitis in November 2023.


List of Conjunctivitis Drugs Key Companies in the Market



  • Akorn Pharmaceuticals (US)

  • Alcon/Novartis AG (Switzerland)

  • Allergan Plc (Ireland)

  • Bausch and Lomb (US)

  • Actavis Plc (US)

  • Pfizer Inc (US)

  • Merck and Co. Inc. (US)

  • Lupin Limited (India)

  • Valeant Pharmaceuticals (Canada)